Adjuvant treatment modalities, prognostic predictors and outcomes of uterine carcinosarcomas

Purpose The purpose of this study is to evaluate the clinicopathological characteristics, treatment, and prognosis of uterine carcinosarcoma (UC). Materials and Methods A retrospective review of three cancer registry databases in Turkey was conducted for identification of patients diagnosed with UC between January 1, 1996, and December 31, 2012. We collected clinicopathological data in order to evaluate factors important in disease- free survival (DFS) and overall survival (OS). Results A total of 66 patients with UC with a median age of 65.0 years were included in the analysis. The median survival time of all patients was 37.5 months and the 5-year OS rate was 59.1%. In early stage patients (I-II) who received adjuvant chemotherapy (CT) with radiation therapy (RT), the median DFS and OS was 44 months and 55 months, respectively, compared to 34.5 months and 36 months, respectively, in patients who received adjuvant RT or CT alone (hazard ratio [HR], 1.4; 95% confidence interval [CI], 0.7 to 3.1 for DFS; p=0.23 and HR, 2.2; 95% CI, 0.9 to 5.3 for OS; p=0.03). In advanced stage patients (III-IV), the median DFS and OS of patients receiving adjuvant RT with CT was 25 months and 38 months, respectively, compared to 23.5 months and 24.5 months, respectively, in patients receiving adjuvant RT or CT alone (HR, 3.1; 95% CI, 0.6 to 16.0 for DFS; p=0.03); (HR, 3.3; 95% CI, 0.7 to 15.0 for OS; p=0.01). In multivariate analysis, advanced International Federation of Gynecology and Obstetrics (FIGO) stage and suboptimal surgery showed significant association with poor OS. Conclusion In patients with early or advanced stage UC, adjuvant CT with RT is associated with improved DFS and OS, as compared to CT or RT alone. © 2015 by the Korean Cancer Association.

Yazar Gungorduk K.
Ozdemir A.
Ertas I.E.
Gokcu M.
Telli E.
Oge T.
Sahbaz A.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/4142
Tek Biçim Adres 10.4143/crt.2014.009
Konu Başlıkları Adjuvant chemotherapy
Adjuvant radiotherapy
Carcinosarcoma
Uterine neoplasms
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı Cancer Research and Treatment
Dergi Cilt Bilgisi 47
Dergi Sayısı 2
Sayfalar 282 - 289
Yayın Yılı 2015
Eser Adı
[dc.title]
Adjuvant treatment modalities, prognostic predictors and outcomes of uterine carcinosarcomas
Yazar
[dc.contributor.author]
Gungorduk K.
Yazar
[dc.contributor.author]
Ozdemir A.
Yazar
[dc.contributor.author]
Ertas I.E.
Yazar
[dc.contributor.author]
Gokcu M.
Yazar
[dc.contributor.author]
Telli E.
Yazar
[dc.contributor.author]
Oge T.
Yazar
[dc.contributor.author]
Sahbaz A.
Yayın Yılı
[dc.date.issued]
2015
Yayıncı
[dc.publisher]
Korean Academy of Periodontology
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Purpose The purpose of this study is to evaluate the clinicopathological characteristics, treatment, and prognosis of uterine carcinosarcoma (UC). Materials and Methods A retrospective review of three cancer registry databases in Turkey was conducted for identification of patients diagnosed with UC between January 1, 1996, and December 31, 2012. We collected clinicopathological data in order to evaluate factors important in disease- free survival (DFS) and overall survival (OS). Results A total of 66 patients with UC with a median age of 65.0 years were included in the analysis. The median survival time of all patients was 37.5 months and the 5-year OS rate was 59.1%. In early stage patients (I-II) who received adjuvant chemotherapy (CT) with radiation therapy (RT), the median DFS and OS was 44 months and 55 months, respectively, compared to 34.5 months and 36 months, respectively, in patients who received adjuvant RT or CT alone (hazard ratio [HR], 1.4; 95% confidence interval [CI], 0.7 to 3.1 for DFS; p=0.23 and HR, 2.2; 95% CI, 0.9 to 5.3 for OS; p=0.03). In advanced stage patients (III-IV), the median DFS and OS of patients receiving adjuvant RT with CT was 25 months and 38 months, respectively, compared to 23.5 months and 24.5 months, respectively, in patients receiving adjuvant RT or CT alone (HR, 3.1; 95% CI, 0.6 to 16.0 for DFS; p=0.03); (HR, 3.3; 95% CI, 0.7 to 15.0 for OS; p=0.01). In multivariate analysis, advanced International Federation of Gynecology and Obstetrics (FIGO) stage and suboptimal surgery showed significant association with poor OS. Conclusion In patients with early or advanced stage UC, adjuvant CT with RT is associated with improved DFS and OS, as compared to CT or RT alone. © 2015 by the Korean Cancer Association.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Adjuvant chemotherapy
Konu Başlıkları
[dc.subject]
Adjuvant radiotherapy
Konu Başlıkları
[dc.subject]
Carcinosarcoma
Konu Başlıkları
[dc.subject]
Uterine neoplasms
Haklar
[dc.rights]
info:eu-repo/semantics/openAccess
ISSN
[dc.identifier.issn]
1598-2998
İlk Sayfa Sayısı
[dc.identifier.startpage]
282
Son Sayfa Sayısı
[dc.identifier.endpage]
289
Dergi Adı
[dc.relation.journal]
Cancer Research and Treatment
Dergi Sayısı
[dc.identifier.issue]
2
Dergi Cilt Bilgisi
[dc.identifier.volume]
47
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.4143/crt.2014.009
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/4142
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
108
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
11 Haziran 2024 01:20
Google Kontrol
Tıklayınız
months patients adjuvant median respectively advanced survival compared receiving evaluate clinicopathological received analysis interval (hazard confidence Purpose showed Association Cancer Korean improved associated Conclusion association significant surgery suboptimal (FIGO) Obstetrics Gynecology Federation International multivariate (III-IV)
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms